Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2021-08-13 00:00:00 ET · period of report 2021-08-11 · accession 0001179110-21-008164 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-13 | 2021-08-11 | CLDX | Heath-Chiozzi Margo | SVP of Regulatory Affairs | M - OptEx | $9.02 | +10.0K | 11.2K | +802% | +$90.2K |
| D | 2021-08-13 | 2021-08-11 | CLDX | Heath-Chiozzi Margo | SVP of Regulatory Affairs | M - OptEx | $0.00 | -10.0K | 8,332 | -55% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-11 | M | A | 10,000 | $9.02 | 11,247 | D | — | — | (F2) This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F1) Includes 247 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| 2 | Derivative | Incentive Stock Option | 2021-08-11 | M | D | 10,000 | $0.00 | 8,332 | D | $9.02 · — to 2028-06-13 | 10,000 Common Stock | (F2) This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F3) 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters |